Court weighs skinny labeling as a path for generic drug competition
TL;DR
The Supreme Court signaled skinny labeling—allowing generics to enter the market for a specific use to avoid patent suits—may survive, potentially preserving a long-standing route to competition under Hatch-Waxman.
- Supreme Court justices appear to signal ‘skinny labeling’ can survive statnews.com
- Justices poised to protect generics manufacturers from liability for decisions of pharmacists about prescribing their products SCOTUSblog
- How a Supreme Court fight over fish oil could raise your prescription drug costs NPR
- Hot Takes: What the Oral Arguments in Hikma/ Amarin Revealed IPWatchdog.com
- Supreme Court takes up generic drug labeling fight Axios
Want the full story? Read the original reporting
Read on statnews.com